Eyes Down For GlaxoSmithKline plc Results

Under the weight of bribery allegations, GlaxoSmithKline plc (LON: GSK) will be bringing us interim figures.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskGlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has been overshadowed a bit of late by takeover attempts at rival AstraZeneca, and its share price has lagged a little — it’s been see-sawing all year and is down around 8% over the past 12 months, to 1,550p.

There’s also a fall in earnings per share (EPS) forecast for the year to December 2014, but the City is expecting a recovery of similar proportions in 2015.

With the market not really knowing what to make of Glaxo right now, first-half results due on 23 July should hopefully help shape our thoughts.

Uncertain first quarter

The pharmaceutical giant’s Q1 figures, released on 30 April, gave us some cause for mixed feelings, with a 2% rise in core EPS at constant exchange rates (CER), to 21p. But that was a little overshadowed by a 20% fall in sterling terms. Total EPS fell 4% at CER and by 30% in sterling.

The company did at least see sales growth in all markets except the US, where it blamed a 10% fall on “competition in respiratory market and quarterly volatility in wholesaler/retailer stocking patterns“.

But the key message at the time was that Glaxo is in a period of change, with chief executive Sir Andrew Witty talking of “the transition we are making to new products in our core franchises of Respiratory and HIV, further R&D delivery and the 3-part transaction we announced last week with Novartis“.

And looking forward, he said “With around 40 NMEs currently in phase II/III development, GSK’s late-stage pipeline remains attractive and we expect the next wave of innovative R&D opportunities to become more visible as this year progresses“.

Bribery accusations

But the pipeline and the firm’s financial picture will not be the only things on investors’ minds right now, not after we heard in May that the UK’s Serious Fraud Office had opened a formal investigation into the company’s commercial practices. That came after Glaxo staff in China had been accused of bribing government and hospital officials, and there are investigations ongoing in Poland too.

For legal reasons the company might not be in a position to say much, if anything, about these issues, but whatever they might be able to say along with their results would be welcome.

Shares look good value

In the meantime, we’re looking at a company that’s predicted to pay a 5.2% dividend yield this year followed by 5.4% next, on a relatively modest P/E of 15 falling to 14. Dividends will probably only be covered around 1.2 to 1.3 times by earnings, mind.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »